Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of fenebrutinib versus teriflunomide in adults with relapsing multiple sclerosis
CTR20212317Phase 3Active
- Sponsor
- Roche
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fenebrutinib, teriflunomide in multiple sclerosis (MS), sponsored by Roche. Started Dec 2021; status: active.
02
Drugs
fenebrutinibteriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on CTR20212317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212317.